Dow Jones
37.891,78 +156,67 (+0,42%) Nasdaq
15.905,93 +20,91 (+0,13%) Nikkei 225
38.471,20 -761,60 (-1,94%) EUR/USD
1,0624 -0,0002 (-0,02%) Bitcoin EUR
59.051,80 -639,16 (-1,07%) CMC Crypto 200
885,54 0,00 (0,00%)
ChemoMetec A/S (0DZ0.L)
| Chiusura precedente | 778,50 |
| Aperto | 791,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 791,00 - 810,50 |
| Intervallo di 52 settimane | 304,00 - 905,00 |
| Volume | |
| Media Volume | 5.187 |
| Capitalizzazione | 120,703M |
| Beta (5 anni mensile) | 1,20 |
| Rapporto PE (ttm) | 1,09 |
| EPS (ttm) | 7,55 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireNotification of managers’ transactions
ANNOUNCEMENT NO. 244 14 September 2023 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CEO Rasmus Kofoed in the attached PDF document. For further information, please contact: Niels Høy Nielsen, CFOTelephone
- GlobeNewswire
Annual Report 2022/23 - Continued solid earnings, but weaker growth amid challenging market conditions
ANNOUNCEMENT NO. 243 13 September 2023 Annual Report 2022/23 (1 July 2022 - 30 June 2023) Continued solid earnings, but weaker growth amid challenging market conditions ChemoMetec’s revenue for 2022/23 grew by 4% to DKK 442.3 million and operating profit (EBITDA) for 2022/23 was DKK 251.0 million, a 13% increase on 2021/22. In 2022/23, ChemoMetec continued developing the new Xcyto platform and the instruments XcytoMatic 40 and XcytoMatic 30. In addition to the XcytoMatic instruments, we expect t
- GlobeNewswire
Guidance for the 2023/24 financial year
ANNOUNCEMENT NO. 242 13 September 2023 Guidance for the 2023/24 financial year ChemoMetec has today approved the annual report for 2022/23, including the guidance for 2023/24, which is considered inside information. For 2023/24, ChemoMetec expects revenue in the range of DKK 400-435 million (2022/23: DKK 442.3 million) and EBITDA in the range of DKK 200-220 (2022/23: DKK 251.0 million). The annual report for 2022/23, which is released along with this announcement, sets out the underlying assumpt
